Caitong International Asset Management Co. Ltd Purchases New Stake in Supernus Pharmaceuticals, Inc. $SUPN

Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,260 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000.

Several other hedge funds have also bought and sold shares of SUPN. LPL Financial LLC grew its position in Supernus Pharmaceuticals by 18.9% in the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company’s stock valued at $461,000 after purchasing an additional 2,029 shares during the period. Wells Fargo & Company MN grew its position in Supernus Pharmaceuticals by 14.4% in the 4th quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after purchasing an additional 7,961 shares during the period. Envestnet Asset Management Inc. grew its position in Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock valued at $2,169,000 after purchasing an additional 3,495 shares during the period. Bank of Montreal Can grew its position in Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after purchasing an additional 473 shares during the period. Finally, Invesco Ltd. grew its position in Supernus Pharmaceuticals by 4.5% in the 4th quarter. Invesco Ltd. now owns 508,069 shares of the specialty pharmaceutical company’s stock valued at $18,372,000 after purchasing an additional 22,027 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SUPN shares. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 140,000 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares of the company’s stock, valued at $43,288,289.66. The trade was a 11.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

SUPN opened at $42.69 on Monday. The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of 37.12 and a beta of 0.74. The firm’s fifty day moving average price is $34.38 and its two-hundred day moving average price is $33.50. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $43.62.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.